{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:48:06Z","timestamp":1762102086392,"version":"build-2065373602"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Department of Research, Development and Education-FoU Halland","award":["RF 185"],"award-info":[{"award-number":["RF 185"]}]},{"name":"Sparbank Varberg, FoU Region Sk\u00e5ne","award":["RF 213"],"award-info":[{"award-number":["RF 213"]}]},{"name":"MAS Cancer Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Cytopathology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD\u2010L1) is a dominant mediator of immunosuppression, binding to programmed cell death 1 (PD\u20101). PD\u2010L1 is up\u2010regulated in cancer cells, and the PD\u20101\/PD\u2010L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy. Further, a correlation between PD\u2010L1 expression and prognosis has been reported. Studies performed on histological material have revealed expression of PD\u2010L1 in MM, but no study has been performed on MM effusions thus far.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>PD\u2010L1 expression was determined by a commercially available antibody (clone 28\u20108) in 74 formalin\u2010fixed, paraffin\u2010embedded cell blocks from body effusions obtained at diagnosis from patients with MM. The presence of MM cells was confirmed with CK5\/6, calretinin, and EMA and the admixture of macrophages was assessed with CD68. Only cases containing more than 100 tumor cells were assessed. Membranous staining in tumor cells was considered positive. Survival time was calculated from the appearance of the first malignant effusion until death.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Reactivity was observed in 23 of 61 (38%) of cases and was classified as \u22651%\u20105% (n = 9 cases), &gt;5%\u201010% (n = 4 cases), &gt;10%\u201050% (n = 4 cases), and &gt;50% (n = 6 cases) positive cells. Survival times did not differ significantly between patients with PD\u2010L1\u2013positive and PD\u2010L1\u2013negative tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>MM effusions are suitable for immune\u2010cytochemical assessment of PD\u2010L1 expression in malignant cells and the results are similar to those reported for histological specimens. <jats:bold><jats:italic>Cancer Cytopathol<\/jats:italic> 2017;125:908\u201017.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncy.21917","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T15:42:55Z","timestamp":1505749375000},"page":"908-917","source":"Crossref","is-referenced-by-count":11,"title":["Determination of PD\u2010L1 expression in effusions from mesothelioma by immuno\u2010cytochemical staining"],"prefix":"10.1002","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0271-3659","authenticated-orcid":false,"given":"Mohammed S. I.","family":"Mansour","sequence":"first","affiliation":[{"name":"Department of Pathology and Cytology Halland Hospital Halmstad Halmstad Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Seidal","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology Halland Hospital Halmstad Halmstad Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Mager","sequence":"additional","affiliation":[{"name":"Division of Lung and Allergy, Department of Clinical Medicine Halland Hospital Halmstad Halmstad Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Baigi","sequence":"additional","affiliation":[{"name":"Department of Primary Health Care, Institute of Medicine, Sahlgrenska Academy Gothenburg University Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[{"name":"Division of Clinical Pathology\/Cytology, Department of Laboratory Medicine, Karolinska Institute Karolinska University Hospital Huddinge Huddinge Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Dejmek","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine in Malm\u00f6 Lund University Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67025-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/10937404.2016.1195323"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031811-124704"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145039"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.07.012"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.02.034"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2326"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003496"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0593-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0428"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1469"},{"key":"e_1_2_8_19_1","first-page":"6501","article-title":"B7\u2010H1 blockade augments adoptive T\u2010cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome SE","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406351101"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1517"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1954-6"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.01.010"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0214-OA"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000377697"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20202"},{"key":"e_1_2_8_32_1","unstructured":"Dako Agilent Pathology Solutions.PD\u2010L1 IHC 28\u20108 pharmDx. Interpretation Manual Non\u2010Squamous Non\u2010Small Cell Lung Cancer (ROW Version).https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29111_pd-l1-ihc-28-8-interpretation-manual.pdf. Accessed April 12 2017."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.03.001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.033"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2016.1117389"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.130"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.02.015"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261241"}],"container-title":["Cancer Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncy.21917","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncy.21917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:22:17Z","timestamp":1760278937000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncy.21917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/cncy.21917"],"URL":"https:\/\/doi.org\/10.1002\/cncy.21917","archive":["Portico"],"relation":{},"ISSN":["1934-662X","1934-6638"],"issn-type":[{"type":"print","value":"1934-662X"},{"type":"electronic","value":"1934-6638"}],"subject":[],"published":{"date-parts":[[2017,9,18]]}}}